ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect – Fierce Biotech

Roche and Zealand Pharma have unveiled new data from the Phase 2 ZUPREME-1 trial at the American Diabetes Association (ADA) 2026 Scientific Sessions, highlighting the potential of petrelintide as a highly effective and well-tolerated weight loss treatment. The mid-stage trial results indicate that petrelintide can help patients shed up to 22.7% of their body weight, while maintaining a remarkably low gastrointestinal (GI) discontinuation rate of 1.5%, suggesting a significant improvement in patient experience over current GLP-1 therapies.

What are the Phase 2 ZUPREME-1 trial results for petrelintide?

The ZUPREME-1 trial, presented during the American Diabetes Association 2026 Scientific Sessions, provides critical evidence for the efficacy of petrelintide in treating overweight and obesity. According to reporting from Reuters, the drug helped patients achieve a weight loss of 22.7% in this mid-stage trial. Other data points from the same phase of testing, as cited by The Clinical Trial Vanguard, noted weight loss of 10.7% among participants.

Beyond the raw percentage of weight lost, the trial focused heavily on the patient experience. A primary goal of the ZUPREME-1 study was to determine if petrelintide could offer a more sustainable weight management path by reducing the side effects often associated with obesity medications. The data suggests that petrelintide is not only effective at reducing mass but is also significantly easier for patients to stay on over the long term.

The following table summarizes the key performance indicators reported across different sources regarding the petrelintide Phase 2 results:

Why is tolerability ‘not to be underappreciated’ in this obesity prospect?

In the current landscape of obesity medicine, efficacy is no longer the only metric of success. While GLP-1 receptor agonists have revolutionized weight loss, they are frequently plagued by gastrointestinal side effects—such as severe nausea, vomiting, and diarrhea—that lead many patients to abandon treatment. This is where the news from the ADA 2026 sessions becomes critical.

“Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect”

As highlighted by Fierce Biotech, the tolerability profile of petrelintide is a cornerstone of its value proposition. When a drug allows for significant weight loss—up to 22.7%—without forcing a large portion of the patient population to quit due to stomach issues, it changes the clinical utility of the medication. The Clinical Trial Vanguard reported a GI discontinuation rate of only 1.5%, a figure that suggests petrelintide may bypass the most common barriers to adherence seen in earlier generations of obesity drugs.

Everyday Health has characterized petrelintide as a “potential GLP-1 alternative,” specifically because it promises weight loss without the debilitating stomach issues that define the current patient experience. For clinicians, a drug that patients can actually tolerate is more valuable than one with slightly higher efficacy but high dropout rates.

How does petrelintide differ from GLP-1 medications?

Petrelintide is an amylin analog, which represents a different biological approach to weight management than the GLP-1 (glucagon-like peptide-1) pathway. While GLP-1 drugs mimic a hormone that increases insulin secretion and slows gastric emptying, amylin analogs target a different set of pathways to regulate appetite and satiety.

The distinction is vital for two reasons:

• Mechanism of Action: By targeting the amylin system, petrelintide aims to redefine the weight management experience for people living with overweight and obesity, as noted in reports from Yahoo Finance.
• Side Effect Profile: The “stomach issues” associated with GLP-1s are often linked to the profound slowing of gastric emptying. Because petrelintide operates via the amylin pathway, it may avoid these specific triggers, leading to the low 1.5% discontinuation rate observed in the ZUPREME-1 trial.

This shift in mechanism allows Roche and Zealand Pharma to position petrelintide not just as another competitor in the weight loss market, but as a solution for the “non-responders” or “non-tolerators” of GLP-1 therapy. This expands the addressable market to include patients who desire the weight loss benefits of modern pharmacology but cannot endure the gastrointestinal distress of existing options.

The role of the American Diabetes Association 2026 Scientific Sessions

The presentation of the ZUPREME-1 data at the ADA 2026 Scientific Sessions is a strategic milestone. The ADA sessions are the premier global venue for unveiling breakthroughs in metabolic health and diabetes care. By debuting these results here, Roche and Zealand Pharma are signaling to the medical community that petrelintide is a serious contender in the metabolic space.

The timing of this announcement is particularly significant as the pharmaceutical industry seeks “next-generation” obesity treatments. The focus has shifted from simply achieving the highest percentage of weight loss to achieving sustainable weight loss. Sustainability is directly tied to tolerability; if a patient cannot tolerate the drug, they cannot maintain the weight loss.

Industry analysts view the ZUPREME-1 data as a validation of the amylin-based approach. The fact that the drug can achieve double-digit weight loss (ranging from 10.7% to 22.7% depending on the metric) while keeping discontinuation rates near negligible levels suggests that the “tolerability gap” in obesity care may finally be closing.

What are the implications for the future of weight management?

The emergence of petrelintide suggests a diversifying future for obesity treatment. Rather than a “one size fits all” approach dominated by GLP-1s, the market is moving toward a diversified toolkit where patients can choose treatments based on their specific biological needs and tolerance levels.

Key implications include:

• Increased Adherence: A 1.5% GI discontinuation rate could lead to much higher long-term adherence rates, meaning more patients actually reach their target weight and maintain it.
• Combination Therapies: While petrelintide is being positioned as an alternative, the different mechanism of action (amylin vs. GLP-1) opens the door for potential combination therapies in the future, which could theoretically maximize weight loss while balancing side effects.
• Market Competition: The entry of a potent amylin analog puts pressure on current market leaders to improve the tolerability of their own pipelines.

For people living with overweight and obesity, this means more options. The “weight management experience,” as described by Yahoo Finance, is being redefined to move away from a trade-off between efficacy and comfort.

As petrelintide moves toward later-stage trials, the medical community will be watching closely to see if these Phase 2 results hold up in larger, more diverse patient populations. If the low discontinuation rate and high efficacy are replicated, the “tolerability” of obesity medication may become the new gold standard for the industry.

For those interested in the broader evolution of these therapies, a related explainer on metabolic hormone analogs may provide further context on how different pathways affect the body.